1. Home
  2. LB vs IMCR Comparison

LB vs IMCR Comparison

Compare LB & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LB
  • IMCR
  • Stock Information
  • Founded
  • LB 1992
  • IMCR 2008
  • Country
  • LB United States
  • IMCR United Kingdom
  • Employees
  • LB N/A
  • IMCR N/A
  • Industry
  • LB
  • IMCR Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • LB
  • IMCR Health Care
  • Exchange
  • LB NYSE
  • IMCR Nasdaq
  • Market Cap
  • LB 1.5B
  • IMCR 1.5B
  • IPO Year
  • LB 2024
  • IMCR 2021
  • Fundamental
  • Price
  • LB $65.25
  • IMCR $29.92
  • Analyst Decision
  • LB Buy
  • IMCR Buy
  • Analyst Count
  • LB 8
  • IMCR 13
  • Target Price
  • LB $55.63
  • IMCR $65.18
  • AVG Volume (30 Days)
  • LB 770.0K
  • IMCR 146.2K
  • Earning Date
  • LB 03-05-2025
  • IMCR 02-26-2025
  • Dividend Yield
  • LB 0.15%
  • IMCR N/A
  • EPS Growth
  • LB N/A
  • IMCR N/A
  • EPS
  • LB 0.30
  • IMCR N/A
  • Revenue
  • LB $90,912,000.00
  • IMCR $296,312,000.00
  • Revenue This Year
  • LB N/A
  • IMCR $28.89
  • Revenue Next Year
  • LB $61.11
  • IMCR $13.00
  • P/E Ratio
  • LB $219.44
  • IMCR N/A
  • Revenue Growth
  • LB 26.93
  • IMCR 25.09
  • 52 Week Low
  • LB $18.75
  • IMCR $27.69
  • 52 Week High
  • LB $84.70
  • IMCR $72.56
  • Technical
  • Relative Strength Index (RSI)
  • LB N/A
  • IMCR 47.96
  • Support Level
  • LB N/A
  • IMCR $28.41
  • Resistance Level
  • LB N/A
  • IMCR $30.49
  • Average True Range (ATR)
  • LB 0.00
  • IMCR 1.47
  • MACD
  • LB 0.00
  • IMCR -0.07
  • Stochastic Oscillator
  • LB 0.00
  • IMCR 41.03

About LB LANDBRIDGE COMPANY LLC

LandBridge Co LLC is engaged in managing land and resources to support and promote oil and natural gas development. It generate revenue streams from the use of its surface acreage, the sale of resources from land and oil and gas royalties.

About IMCR Immunocore Holdings plc

Immunocore Holdings PLC is a late-stage biotechnology company engaged in the development of a novel class of TCR bispecific immunotherapies for the treatment of cancer, infectious and autoimmune diseases. Its geographical segments are the United Kingdom and the United States, of which the majority of its revenue comes from the United States.

Share on Social Networks: